Document is current
Any future updates will be listed below
-
Authors
Tian, Zhuang https://orcid.org/0000-0003-1140-4062
Li, Xiaoyan
Li, Liwen
Zhang, Qing
Wang, Jian’an https://orcid.org/0000-0002-4583-3204
Shi, Yunqi
Peng, Daoquan
Ma, Wei https://orcid.org/0000-0003-1305-3980
Yang, Ping
Cheng, Xiang https://orcid.org/0000-0002-6287-3128
Jin, Wei https://orcid.org/0000-0002-2905-2109
Wang, Fang https://orcid.org/0000-0002-6674-5537
Memaj, Arteid
Xie, Yimeng
Pan, Beth
Florea, Victoria
Zheng, Jing
Zhong, Yue
Zhang, Shuyang https://orcid.org/0000-0002-1532-0029
-
Funding
Funding for this research was provided by:
Shanghai LianBio Development Co., Ltd
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 30 January 2026
Accepted: 23 April 2026
First Online: 21 May 2026
Declarations
:
: Arteid Memaj, Yimeng Xie, Beth Pan, Victoria Florea, Jing Zheng, and Yue Zhong are employees of Bristol Myers Squibb and own stocks of Bristol Myers Squibb. Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’an Wang, Yunqi Shi, Daoquan Peng, Wei Ma, Ping Yang, Xiang Cheng, Wei Jin, Fang Wang, and Shuyang Zhang have no conflicts of interest to declare.
: This trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice. Institutional review boards/independent ethics committees (listed in Supplementary Table ) at each site approved the protocol. The study complied with country-specific regulatory requirements relating to safety reporting to the regulatory authority, institutional review boards/independent ethics committees, and investigators. All patients provided written informed consent to participate prior to entering the study. This study was funded by Shanghai LianBio Development Co., Ltd and Bristol Myers Squibb.
